ClinicalTrials.gg
Status unknownNCT04475978Updated Nov 1, 2022

Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon Treatment for STEMI Patients:a Prospective, Multicenter, Randomized Controlled Trial

An interventional study of IVUS-guide DCB PTCA and Angio-guide DCB PTCA in STEMI, sponsored by Xiamen Cardiovascular Hospital, Xiamen University. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Xiamen Cardiovascular Hospital, Xiamen University · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 40 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
65th of 97
208 · median 320
Started
2020
with 8 others
No phase
51 of 146
21 open now
Registered
71st of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 65th largest by planned enrollment of the 97 interventional ones that give a count, is one of 9 that started in 2020, is one of 51 with no phase, and was the 71st registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

40 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

Objectives: The present study aimed to investigate the difference in late luminal loss (LLL) at 9-month after drug-coated balloon (DCB) treatment with intravascular ultrasound (IVUS) versus angiography for ST-segment elevated myocardial infarction (STEMI)patients.

Background: In primary percutaneous coronary intervention for STEMI, DCB angioplasty has proved to be a safe and feasible strategy. Compare with angiography guidance, IVUS-guided PCI significantly improve clinical outcome. With IVUS guidance, STEMI patients undergo DCB angioplasty might have be beneficial results.

Methods: A total of 208 STEMI patients who required DCB treatment were randomly assigned either an IVUS guidance and angiography guidance group. The primary endpoint was late luminal loss at 9-month. Stent thrombosis (ST) was the safety endpoint.

03

Conditions studied

  • STEMI

Keywords

  • STEMI
  • drug-coated balloon
  • IVUS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute myocardial infarction eligible for PPCI:

    1. >20 min of chest-pain and at least 1 mm ST-elevation in at least two contiguous leads, a new left bundle branch block or a true posterior myocardial infarction (confirmed by or echocardiography) .
    2. Reperfusion is expected to be feasible within 12 h after onset of complaints.
  • Infarct related artery eligible for PPCI and:

    1. De novo lesion in a native coronary artery
    2. Reference-vessel diameter 2.5 mm and 4 mm
    3. Diameter stenosis of >50% (by visual assessment) after thrombus aspiration and pre-dilatation.

Exclusion criteria

Exclusion Criteria:

    • Age \<18 yr and >85 yr
  • History of myocardial infarction
  • lesion length > 30m
  • Left Main lesion
  • Ostial lesion
  • None-target vessel need to treat with PCI
  • Severe calcification
  • Severe tortuosity
  • Severe angulation
  • Cardiogenic shock before pre-dilation or any serious cases can not perform IVUS
  • Known /resistance for bivalirudin, fondaparinux, heparin, aspirin, prasugrel and/or ticagrelor
  • Participation in another clinical study, interfering with this protocol Uncertain
  • Known intracranial disease (mass, aneurysm, AVM, haemorrhagic CVA, ischemic CVA/ \<6 months before inclusion or ischemic CVA with permanent neurological deficit) Gastrointestinal/urinary tract
  • bleeding \<2 months before inclusion Refusal to receive blood transfusion
  • Planned major surgery within 6 weeks
  • Stent implantation \<1 week before inclusion
  • Expected mortality from any cause within the next 12 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    IVUS group

    Device: IVUS-guide DCB PTCA

  • Placebo comparator
    Angio group

    Device: Angio-guide DCB PTCA

Interventions

  • DeviceIVUS-guide DCB PTCA

    IVUS-guide DCB PTCA

  • DeviceAngio-guide DCB PTCA

    Angio-guide DCB PTCA

06

What researchers measure

Primary outcomes

  1. late lumen loss(LLL)

    late lumen loss(LLL)

    Time frame: At 9 months follow-up

Secondary outcomes

  1. target lesion failure (TLF)

    the composite of car- diac death, target-vessel MI (TVMI), or clinically driven TLR

    Time frame: At 1-year follow-up

07

Study locations

1 of 1 sites recruiting
  • Xiamen Cardiovascular Hospital Xiamen University
    Xiamen, Fujian 361000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Jan 2023, 32 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 32 months is below that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2020
First posted
Jul 17, 2020
StartActual
May 25, 2020
Primary completionEst.
Jan 31, 2023
CompletionEst.
Mar 30, 2023
Last update
Nov 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04475978
Lead sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Responsible party
Sponsor
First posted
Jul 17, 2020
Start date
May 25, 2020
Primary completion
Jan 31, 2023 (estimated)
Completion
Mar 30, 2023 (estimated)
Last update
Nov 1, 2022

Study contacts

Xiang Chen, MD
Contact
Seanchenx@126.com
18033997788
Yulin Zhou, Ph.D
principal investigator · Clinical Trial Center of Xiamen Cardiovascular Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion